# Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease

> **NCT00209014** · PHASE2 · TERMINATED · sponsor: **Emory University** · enrollment: 2 (actual)

## Conditions studied

- B-Cell Lymphoma
- Hodgkin's Disease

## Interventions

- **DRUG:** Thalidomide

## Key facts

- **NCT ID:** NCT00209014
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-07
- **Primary completion:** —
- **Final completion:** 2006-06
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Celgene unable to continue funds.
- **Last updated:** 2009-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00209014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00209014, "Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00209014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*